If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
Zepbound ® (tirzepatide) injection
2.5 mg/ 5 mg/ 7.5 mg/ 10 mg/ 12.5 mg/ 15 mg
This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
After withdrawing the Zepbound® (tirzepatide) dose from the vial, can the remaining solution be kept for a future dose?
Tirzepatide does not contain a preservative and should be injected as soon as the needle has punctured the vial septum and the solution has been removed from the vial. Any remaining solution in the vial, after withdrawing the dose, should be discarded.
See important safety information, including boxed warning, in the attached prescribing information.
Extracting Additional Doses From a Tirzepatide Single-Dose Vial
Tirzepatide is a once-weekly injection for subcutaneous (SC) use. It is supplied in a single-dose vial.1
Extracting additional doses of tirzepatide from the single-dose vial for future use is not recommended.1
The tirzepatide vial is for single-dose use and does not contain a preservative.2
The tirzepatide vial should be injected as soon as the needle is pushed through the rubber stopper and the solution removed from the vial.1
Throw away all opened vials after use, even if there is medicine left in the vial.1
According to the Centers for Disease Control and Prevention (CDC), vials designated as single-dose are for a single injection in a single patient.3
Withdrawing additional doses, or pooling (combining) leftover medication, from single-dose vials for future use may increase risks of vial contamination and infection.3
Eli Lilly and Company has not studied the use of leftover tirzepatide after withdrawal of the recommended dose from a single-dose vial. Therefore, there is no clinical information available on this topic.
Enclosed Prescribing Information
References
1Zepbound Single-Dose Vial [instructions for use]. Indianapolis, IN: Eli Lilly and Company; 2024.
2Zepbound [package insert]. Indianapolis, IN: Eli Lilly and Company; 2024.
3Centers for Disease Control and Prevention (CDC). Preventing Unsafe Injection Practices. March 2024. Accessed July 23, 2024. https://www.cdc.gov/injection-safety/hcp/clinical-safety/
4Zepbound [medication guide]. Indianapolis, IN: Eli Lilly and Company; 2024.
Date of Last Review: June 07, 2024